We recently developed a sensitive assay for 3',5'-cAMP using high performance liquid chromatography-tandem mass spectrometry. Using this assay, we investigated the release of 3',5'-cAMP from isolated, perfused rat kidneys. To our surprise, we observed a dominant chromatographic peak that was due to an endogenous substance that had the same parent ion as 3',5'-cAMP and that fragmented to the same daughter ion (adenine) as 3',5'-cAMP. However, the retention time of this unknown was approximately 2.9 minutes compared to 6.3 minutes for authentic 3',5'-cAMP. We hypothesized that the unknown substance was an isomer of 3',5'-cAMP. Indeed, the unknown substance had the same retention time and mass spectral properties as authentic 2',3'-cAMP. Renal venous secretion of 2',3'-cAMP was greater in kidneys from 20-week-old genetically-hypertensive rats compared with age-matched normotensive rats (12.49 ± 2.14 versus 5.32 ± 1.97 ng/min per gram kidney weight, respectively; n=18). Isoproterenol (1 μmol/L; β -adrenoceptor agonist) increased renal venous 3',5'-cAMP secretion (approximately 690% of control), but had no effect on 2',3'-cAMP production. In contrast, rapamycin (0.2 μmol/L; activator of mRNA turnover) and iodoacetate + 2,4-dinitrophenol (50 μmol/L; metabolic inhibitors) increased the renal venous secretion of 2',3'-cAMP (approximately 1000 % and 4100 % of control, respectively) while simultaneously decreasing the renal venous secretion of 3',5'-cAMP. In conclusion, 2',3'-cAMP is a naturally-occurring isomer of 3',5'-cAMP that is: 1) not made by adenylyl cyclase; 2) released from kidneys into the extracellular compartment;
INTRODUCTION
Because 3',5'-cAMP is an important second messenger in most cells comprising organ systems, it is desirable to be able to investigate, with a high level of precision, the production of 3',5'-cAMP in intact organs. In this regard, it is fortunate that intracellular 3',5'-cAMP is robustly transported to the extracellular compartment by various active transporters, including multidrug resistance protein (MRP) 4 and MRP5 (Kruh et al., 2001; Deeley et al., 2006) .
Consequently, increases in intracellular levels of 3',5'-cAMP can be detected by measuring 3',5'-cAMP in the venous effluent of organ systems, such as the kidney (Vyas et al., 1996) .
With regard to the kidney, 3',5'-cAMP is importantly involved in regulation of renal vascular resistance, glomerular filtration rate, renin release, tubular epithelial transport and the actions of hormones such as antidiuretic hormone (Cheng and Grande, 2007) . Moreover, many of these physiological parameters are altered in kidneys from chronically-hypertensive animals, compared with normotensive animals, in part because of target organ damage induced by the chronic elevation of arterial blood pressure.
To study the role of 3',5'-cAMP in the hypertensive kidney, we recently developed an assay to measure 3',5'-cAMP in the renal venous effluent from isolated, perfused kidneys (Ren et al., 2008) . Unlike the commercially available kits for 3',5'-cAMP that rely upon the selectivity of antibody recognition, our assay was based on the platform technology of highperformance liquid chromatography-tandem mass spectrometry (Ren et al., 2008) .
While investigating the production of 3',5'-cAMP from isolated, perfused kidneys obtained from normotensive and hypertensive rats, we observed the release of a substance with This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on November 25, 2008 as DOI: 10.1124 at ASPET Journals on April 1, 2017 jpet.aspetjournals.org Downloaded from mass spectral characteristics similar to 3',5'-cAMP, but that was clearly not 3',5'-cAMP. The purpose of this report is to describe the identification and quantification of this substance and to describe its origin and regulation.
This article has not been copyedited and formatted. The final version may differ from this version. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Isolated, Perfused Kidney Preparation. Rats were anesthetized with Inactin (90 mg/kg, i.p.; Sigma-Aldrich, St. Louis, MO), and the left kidney was isolated and perfused with Tyrode's solution containing 3-isobutyl-1-methylxanthine (10 μmol/L; an inhibitor of phosphodiesterases; Sigma-Aldrich, St. Louis, MO) using a Hugo Sachs Elektronik-Harvard Apparatus GmbH (March-Hugstetten, Germany) kidney perfusion system as previously described (Gao et al., 2003) . Briefly, all branches of the left renal artery and vein were ligated. A polyethylene-50 cannula was placed into the left renal artery, and a polyethylene-90 cannula was placed into the left renal vein. The left kidney was removed, attached to the perfusion system and kidneys were perfused (single pass mode) at a constant flow (5 ml/min), and perfusion pressure was monitored with a pressure transducer.
Protocols. Kidneys were isolated from adult SHR and WKY and perfused in vitro as described above. After a 30 to 60-minute stabilization period, perfusate exiting the renal vein was collected for 1 minute and immediately placed on ice. Next, in some experiments, isoproterenol (a β -adrenoceptor agonist; 1 μmol/L; Sigma-Aldrich) was added to the arterial perfusate, and five minutes later another 1-minute renal venous sample was collected. In other experiments, after the basal sample of venous perfusate was collected, the kidney was treated This article has not been copyedited and formatted. The final version may differ from this version. with either rapamycin (0.2 μmol/L; Sigma-Aldrich) or iodoacetate + 2,4-dinitrophenol (50 μmol/L each; Sigma-Aldrich) and venous sampling was repeated at the indicated times.
High Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
3',5'-cAMP and 2',3'-cAMP were purchased from Sigma-Aldrich. The internal standard ( 13 C 10 -adenosine) was from Medical Isotopes Inc. (Pelham, NH). All standards were stored at -20°C, and the internal standard was stored at -80°C. Solutions of standards (50 ng/μL) and internal standard (1 ng/μL) were prepared in ultrapure water and stored at -20°C. The mixed solution of cAMPs (1 ng/μL) was prepared each day by dilution in ultrapure water and kept at 4°C.
Additional dilutions of standards were prepared from this solution by serial dilution. Methanol (for LC-MS/MS) was from Riedel-Dehae (Seelze, Germany), and analytical grade formic acid was from Fluka (Buchs, Switzerland).
3',5'-cAMP and 2',3'-cAMP were resolved by reversed-phase LC (Agilent Zorbax eclipse XDB-C-18 column, 3.5 μm beads; 2.1x100 mm) and quantified using a triple quadrupole MS (TSQ Quantum-Ultra, ThermoFisher Scientific, San Jose, CA) operating in the selective reaction monitoring (SRM) mode with a heated electrospray ionization source. The mobile phases were delivered by an ultra pressure LC system (Accela, ThermoFisher Scientific, San
Jose, CA) and consisted of linear gradient changes involving two buffers: Buffer A was 0.1% formic acid in water; Buffer B was 0.1% formic acid in methanol. The mobile phase flow rate was 300 μL/min. The gradient (A/B) was: 0 to 2 min, 98.5%/1.5%; 2 to 4 min, to 98%/2%; 5 to 6 min, to 92%/8%; 7 to 8 min, to 85%/15%; 9 to 11.5 min, to 98.5%/1.5%. Sample tray temperature was set at 4°C and the column temperature was kept at 20°C.
For maximum sensitivities, instrument parameters were optimized as follows: ion spray β -adrenoceptors, the 3',5'-cAMP peak was greatly increased, whereas the unknown peak was not ( Figure 2 ). Thus, it was unlikely that the unknown peak was endogenous 3',5'-cAMP. For the unknown substance giving rise to the peak at 2.9 minutes to be observed, the substance would have to have a parent ion of 330 m/z (molecular weight of 3',5'-cAMP plus 1) with a daughter fragment of 136 m/z (molecular weight of adenine fragment plus 1). We hypothesized, therefore, that the unknown substance was a positional isomer of 3',5'-cAMP, possibly 2',3'-cAMP. Because, at least to our knowledge, 2',3'-cAMP has not been reported as an endogenous product released from intact cells, tissues or organs, we thought it necessary to secure the identity of the putative 2',3'-cAMP peak. Therefore, we obtained authentic 2',3'-cAMP and determined its retention time relative to the unknown substance using our LC-MS/MS system, again with selective reaction monitoring (SRM; 330 m/z→ 136 m/z). As shown in increased from 545,047 arbitrary units to 1,763,662 arbitrary units with the addition of authentic 2',3'-cAMP, and the ratio of the area under the putative 2',3'-cAMP peak to the area under the 3',5'-cAMP peak increased from 1.69 to 3.24. Thus, addition of authentic 2',3'-cAMP increased the signal of the putative 2',3'-cAMP peak without introducing any new peaks in the chromatogram. This indicated that the substance giving rise to the putative 2',3'-cAMP peak had the precise retention time, parent ion and daughter ion of authentic 2',3'-cAMP.
RESULTS

As
To further secure the identity of the substance giving rise to the putative 2',3'-cAMP peak, we injected authentic 2',3'-cAMP and authentic 3',5'-cAMP into the LC-MS/MS system, and then acquired mass spectral scans from 100 m/z to 400 m/z at different collision energies to fragment the parent ion. As shown in Figure 4A , at a collision energy of 10 V, both authentic 2',3'-cAMP and authentic 3,'5',-cAMP gave rise to a mass spectrum consisting of mainly the parent ion (330 m/z). Thus, 10 V was insufficient to fragment the parent ion of either form of cAMP. However, when the collision energy was increased to 18 V ( Figure 4B ), there was substantial fragmentation of authentic 2',3'-cAMP to the 136 m/z fragment; in fact the 136 m/z fragment became the most abundant ion. In contrast, although authentic 3',5'-cAMP showed some fragmentation at 18 V of collision energy, the 330 m/z remained the most abundant ion.
For both forms of cAMP, at a collision energy of 23 V, mainly the 136 m/z daughter ion was observed ( Figure 4C ). These data indicate that 2',3'-cAMP can be further identified and differentiated from 3',5'-cAMP by using the collision energy necessary to fragment the parent ion.
As shown in Figure 5A , when renal venous perfusate was injected into the LC-MS/MS and a mass spectral scan was obtained at the center of the putative 2',3'-cAMP peak and the 3',5'-cAMP peak, at 10 V of collision energy, only a single mass was observed at 330 m/z for This article has not been copyedited and formatted. The final version may differ from this version. both peaks. Importantly, when the collision energy was increased to 18 V ( Figure 5B ), for the putative 2',3'-cAMP peak, the major fragment was 136 m/z; whereas for the 3',5'-cAMP peak, the major fragment was still 330 m/z. At 23 V of collision energy ( Figure 5C ), both the putative 2',3'-cAMP and 3',5'-cAMP peaks gave rise mainly to a daughter ion of 136 m/z. Thus the susceptibility of the putative 2',3'-cAMP peak to fragmentation by collision energy was very similar to that observed for authentic 2',3'-cAMP and was different from that observed for 3',5'-cAMP.
Taken together, the above results indicate that the putative 2',3'-cAMP peak was indeed, and without any reasonable doubt, 2',3'-cAMP. Therefore, we turned our attention to quantifying the amounts of 2',3'-cAMP versus 3',5'-cAMP release from isolated, perfused kidneys obtained from 20 week-old SHR and WKY rats. As shown in Figure 6 , the basal renal venous secretion of 3',5'-cAMP was similar in SHR versus WKY kidneys and was significantly (p<0.0001) and similarly increased by isoproterenol (7.7-fold and 6.2-fold in SHR and WKY kidneys, respectively). In contrast, the renal venous 2,',3'-cAMP secretion was 2.4-fold greater (p=0.0052) in SHR compared with WKY kidneys and isoproterenol had no effect on the renal venous secretion of 2',3'-cAMP ( Figure 7 ).
Biochemical studies suggest that 2',3'-cAMP can be produced by RNases (Thompson et al., 1994) , and recent evidence supports enhanced mRNA turnover in SHR tissues (Klöss et al., 2005) . Therefore, we hypothesized that 2',3'-cAMP may derive from degradation of mRNA.
To test this hypothesis we used two approaches to accelerate mRNA turnover. One approach was infusion of rapamycin, a drug that activates mRNA turnover via the mTOR pathway (Banholzer et al., 1997; Hashemolhosseini et al., 1998; Albig and Decker, 2001) , into the kidney.
In this experimental series, 4 kidneys were from SHR and 4 were from WKY; however, the This article has not been copyedited and formatted. The final version may differ from this version. Because previously published studies show that tissue ischemia triggers mRNA degradation (Akahane et al., 2001a; Akahane et al., 2001b; Almeida et al., 2004) , in a second approach to stimulate mRNA degradation, we treated kidneys with a combination of metabolic inhibitors (iodoacetate, inhibitor of glycolysis; 2,4-dinitrophenol, inhibitor of oxidative phosphorylation). In this experimental series, 4 kidneys were from SHR and 2 were from WKY;
however, as with the rapamycin study the results were similar so the data were combined. As shown in Figure 9 The biochemical findings in isolated systems described above suggest, but do not prove, that mRNA degradation is the source of 2',3'-cAMP from intact tissues. Importantly, the present study demonstrates that both rapamycin and metabolic inhibitors cause a massive increase in the renal venous secretion of 2',3'-cAMP while simultaneously decreasing the renal production of 3',5'-cAMP. These findings add support to the conclusion that mRNA is the source of 2',3'-cAMP released from the isolated, perfused kidney because both rapamycin (Banholzer et al., 1997; Hashemolhosseini et al., 1998; Albig and Decker, 2001) , 1970; Kuster et al., 1973; Cramer and Lindl, 1974; King and Mayer, 1974; Doore et al., 1975; O'Brien and Strange, 1975; Brunton and Mayer, 1979; Barber and Butcher, 1983; Fehr et al., 1990; Kather, 1990; Li et al., 2007; Chiavegatti et al., 2008; Giron et al., 2008) conserved AU-rich elements (AREs; AUUUA) in the 3'-untranslated region (3'-UTR) (Fan and Steitz, 1998) . AREs are targeted for rapid mRNA decay, and thus the presence of AREs within the 3'-UTR of numerous mRNAs plays a critical role in regulating mRNA stability and degradation (Fan and Steitz, 1998) . Therefore, a reduction in human-antigen R in organs from animals with long-standing hypertension would be predicted to result in decreased mRNA stability, increased mRNA degradation and therefore increased extracellular levels of 2',3'-cAMP.
In the present study we were able to differentiate 2',3'-cAMP from 3',5'-cAMP using LC-MS/MS. Do commercially available assay kits for 3',5'-cAMP discern between these positional isomers of cAMP? Although we cannot generalize to all commercially available kits,
we have examined the popular Amersham cAMP Biotrak Enzymeimmunoassay System (GE Healthcare, Piscataway, NJ) and find that this kit does not detect 2',3'-cAMP.
In summary, this study shows for the first time that 2',3'-cAMP is produced by an intact organ and is secreted into the extracellular compartment. It is noteworthy that polyadenine tails of mRNA would provide a large cellular reservoir of potential 2',3'-cAMP, that hydrolysis of the polyadenine tail of eukaryotic mRNA is an early event in mRNA turnover/breakdown and that 2',3'-cAMP is likely transported to the extracellular compartment. Thus it is conceivable that an important role of the polyadenine tail of mRNA is to provide, in response to tissue injury, extracellular 2',3'-cAMP which might then mediate biological functions, for example tissue protection, and this possibility is under investigation.
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